A three-stage biophysical screening cascade for fragment-based drug discovery

Nature Protocols

Volumn 8, Issue 11, 2013, Pages 2309-2324

  Mashalidis, Ellene H ^a,b   Śledå, Paweł ^a,c   Lang, Steffen ^a   Abell, Chris ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BINDING AFFINITY; BIOPHYSICS; CHEMICAL ANALYSIS; CHEMICAL INTERACTION; CONTROLLED STUDY; DIFFERENTIAL SCANNING FLUORIMETRY; DRUG DEVELOPMENT; FLUOROMETRY; FRAGMENT BASED DRUG DISCOVERY; ISOTHERMAL TITRATION CALORIMETRY; LIGAND BINDING; MACROMOLECULE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; SCREENING; VALIDATION PROCESS; X RAY CRYSTALLOGRAPHY;

CALORIMETRY; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; FLUOROMETRY; HYDROGEN BONDING; INDOLES; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; PEPTIDE SYNTHASES; SMALL MOLECULE LIBRARIES;

EID: 84887001050     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2013.130     Document Type: Article

References (62)

1. Murray, C.W. & Rees, D.C. The rise of fragment-based drug discovery. Nat. Chem. 1, 187-192 (2009).
2. Ciulli, A. & Abell, C. Fragment-based approaches to enzyme inhibition. Curr. Opin. Biotechnol. 18, 489-496 (2007).
3. Congreve, M., Carr, R., Murray, C. & Jhoti, H. A ?rule of three? for fragment-based lead discovery? Drug Discov. Today 8, 876-877 (2003). (Pubitemid 37194496)
4. Hung, A. et al. Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase. Angew. Chem. Int. Ed. 48, 8452-8456 (2009).
5. Hudson, S.A. et al. Application of fragment screening and merging to the discovery of inhibitors of the Mycobacterium tuberculosis cytochrome P450 CYP121. Angew. Chem. Int. Ed. 51, 9311-9316 (2012).
6. Hajduk, P.J. et al. Design of adenosine kinase inhibitors from the NMR-based screening of fragments. J. Med. Chem. 43, 4781-4786 (2000). (Pubitemid 32002689)
7. Gill, A., Cleasby, A. & Jhoti, H. The discovery of novel protein kinase inhibitors by using fragment-based high-throughput X-ray crystallography. Chembiochem. 6, 506-512 (2005). (Pubitemid 40868138)
8. Liu, G. et al. Fragment screening and assembly: A highly efficient approach to a selective and cell active protein tyrosine phosphatase 1B inhibitor. J. Med. Chem. 46, 4232-4235 (2003). (Pubitemid 37153003)
9. Chen, L., Cressina, E., Leeper, F.J., Smith, A.G. & Abell, C. A fragment-based approach to identifying ligands for riboswitches. ACS Chem. Biol. 5, 355-358 (2010).
10. Petros, A.M. et al. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J. Med. Chem. 49, 656-663 (2006). (Pubitemid 43157495)
11. Scott, D.E. et al. Using a fragment-based approach to target protein-protein interactions. Chembiochem. 14, 332-342 (2013).
12. FDA approves vemurafenib for treatment of metastatic melanoma. Oncology 25, 906 (2011).
13. Baker, M. Fragment-based lead discovery grows up. Nat. Rev. Drug Discov. 12, 5-7 (2012).
14. Erlanson, D. (Ed.) Practical Fragments ?http://practicalfragments. blogspot.com/?.
15. Chessari, G. & Woodhead, A.J. From fragment to clinical candidate-a historical perspective. Drug Discov. Today 14, 668-675 (2009).
16. Scott, D.E., Coyne, A.G., Hudson, S.A. & Abell, C. Fragment-based approaches in drug discovery and chemical biology. Biochemistry 51, 4990-5003 (2012).
17. Śledź, P., Abell, C. & Ciulli, A. Ligand-observed NMR in fragment-based approaches. in NMR of Biomolecules: Towards Mechanistic Systems Biology 1st edn. (eds. Bertini, I., McGreevy, K.S. & Parigi, G.), 265-281 (Wiley-VCH, 2012).
18. Kranz, J.K. & Schalk-Hihi, C. Protein thermal shifts to identify low molecular weight fragments. Methods Enzymol. 493, 277-298 (2011).
19. Hartshorn, M.J. et al. Fragment-based lead discovery using X-ray crystallography. J. Med. Chem. 48, 403-413 (2005). (Pubitemid 40139783)
20. Blundell, T.L., Jhoti, H. & Abell, C. High-throughput crystallography for lead discovery in drug design. Nat. Rev. Drug Discov. 1, 45-54 (2002). (Pubitemid 37361403)
21. Navratilova, I. & Hopkins, A.L. Fragment screening by surface plasmon resonance. ACS Med. Chem. Lett. 1, 44-48 (2010).
22. Hofstadler, S.A. & Sannes-Lowery, K.A. Applications of ESI-MS in drug discovery: interrogation of noncovalent complexes. Nat. Rev. Drug Discov. 5, 585-595 (2006). (Pubitemid 43971193)
23. Arkin, M.R. & Wells, J.A. Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream. Nat. Rev. Drug Discov. 3, 301-317 (2004). (Pubitemid 38499758)
24. Śledź, P., Lang, S., Stubbs, C.J. & Abell, C. High-throughput interrogation of ligand binding mode using a fluorescence-based assay. Angew. Chem. Int. Ed. 51, 7680-7683 (2012).
25. Śledź, P. et al. From crystal packing to molecular recognition: Prediction and discovery of a binding site on the surface of polo-like kinase. Angew. Chem. Int. Ed. 50, 4003-4006 (2011).
26. Tan, Y.S. et al. Using ligand-mapping simulations to design a ligand selectively targeting a cryptic surface pocket of polo-like kinase.Angew. Chem. Int. Ed. 51, 10078-10081 (2012).
27. Schuffenhauer, A. et al. Library design for fragment based screening. Curr. Top Med. Chem. 5, 751-762 (2005). (Pubitemid 41179715)
28. Siegal, G., Ab, E. & Schultz, J. Integration of fragment screening and library design. Drug Discov. Today 12, 1032-1039 (2007). (Pubitemid 350180558)
29. Hung, A.W. et al. Route to three-dimensional fragments using diversity-oriented synthesis. Proc. Natl. Acad. Sci. USA 108, 6799-6804 (2011).
30. Over, B. et al. Natural-product-derived fragments for fragment-based ligand discovery. Nat. Chem. 5, 21-28 (2013).
31. Tounge, B.A. & Parker, M.H. Designing a diverse high-quality library for crystallography-based FBDD screening. Methods Enzymol. 493, 3-20 (2011).
32. Davis, B.J. & Erlanson, D.A. Learning from our mistakes: The ?unknown knowns? in fragment screening. Bioorg. Med. Chem. Lett. 2, 2844-2852 (2013).
33. Alsenz, J. & Kansy, M. High throughput solubility measurement in drug discovery and development. Adv. Drug Delivery Rev. 59, 546-567 (2007). (Pubitemid 47285404)
34. Kozikowski, B.A. et al. The effect of freeze/thaw cycles on the stability of compounds in DMSO. J. Biomol. Screen 8, 210-215 (2003).
35. Poklar, N., Lah, J., Salobir, M., Macek, P. & Vesnaver, G. pH and temperature-induced molten globule-like denatured states of equinatoxin II: A study by UV-melting, DSC, far-and near-UV CD spectroscopy, and ANS fluorescence. Biochemistry 36, 14345-14352 (1997). (Pubitemid 27509926)
36. Pantoliano, M.W. et al. High-density miniaturized thermal shift assays as a general strategy for drug discovery. J. Biomol. Screen 6, 429-440 (2001). (Pubitemid 34052847)
37. Lo, M.-C. et al. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal. Biochem. 332, 153-159 (2004). (Pubitemid 39099482)
38. Niesen, F.H., Berglund, H. & Vedadi, M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2, 2212-2221 (2007). (Pubitemid 351565860)
39. Zhang, R. & Monsma, F. Fluorescence-based thermal shift assays. Curr. Opin. Drug Discov. Devel. 13, 389-402 (2010).
40. Ericsson, U.B., Hallberg, B.M., Detitta, G.T., Dekker, N. & Nordlund, P. Thermofluor-based high-throughput stability optimization of proteins for structural studies. Anal. Biochem. 357, 289-298 (2006). (Pubitemid 44430091)
41. Tjernberg, A., Markova, N., Griffiths, W.J. & Hallen, D. DMSO-related effects in protein characterization. J. Biomol. Screen 11, 131-137 (2006).
42. Shuker, S.B., Hajduk, P.J., Meadows, R.P. & Fesik, S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274, 1531-1534 (1996). (Pubitemid 26403929)
43. Lepre, C.A., Moore, J.M. & Peng, J.W. Theory and applications of NMR-based screening in pharmaceutical research. Chem. Rev. 104, 3641-3676 (2004).
44. Jhoti, H., Cleasby, A., Verdonk, M. & Williams, G. Fragment-based screening using X-ray crystallography and NMR spectroscopy. Curr. Opin. Chem. Biol. 11, 485-493 (2007). (Pubitemid 47588996)
45. Mayer, M. & Meyer, B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem. Int. Ed. 38, 1784-1788 (1999). (Pubitemid 29290947)
46. Dalvit, C., Fogliatto, G., Stewart, A., Veronesi, M. & Stockman, B. WaterLOGSY as a method for primary NMR screening: Practical aspects and range of applicability. J. Biomol. NMR 21, 349-359 (2001). (Pubitemid 34071389)
47. Carr, Y.H. & Purcell, M.E. Effects of diffusion on free precession in nuclear magnetic resonance experiments. Phys. Rev. 94, 630-638 (1954).
48. Meiboom, S. & Gill, D. Modified spin-echo method for measuring nuclear relaxation times. Rev. Sci. Instrum. 29, 688-691 (1958).
49. Pellecchia, M. et al. Perspectives on NMR in drug discovery: A technique comes of age. Nat. Rev. Drug Discov. 7, 738-745 (2008).
50. Dalvit, C. NMR methods in fragment screening: Theory and a comparison with other biophysical techniques. Drug Discov. Today 14, 1051-1057 (2009).
51. Angulo, J. & Nieto, P.M. STD-NMR: Application to transient interactions between biomolecules-a quantitative approach. Eur. Biophys. J. 40, 1357-1369 (2011).
52. Dalvit, C. et al. Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J. Biomol. NMR 18, 65-68 (2000).
53. Hajduk, P.J., Olejniczak, E.T. & Fesik, S.W. One-dimensional relaxation-and diffusion-edited NMR methods for screening compounds that bind to macromolecules. J. Am. Chem. Soc. 119, 12257-12261 (1997). (Pubitemid 28078713)
54. Leavitt, S. & Freire, E. Direct measurement of protein binding energetics by isothermal titration calorimetry. Curr. Opin. Struct. Biol. 11, 560-566 (2001). (Pubitemid 32972017)
55. Turnbull, W.B. & Daranas, A.H. On the value of c: Can low affinity systems be studied by isothermal titration calorimetry? J. Am. Chem. Soc. 125, 14859-14866 (2003). (Pubitemid 37475576)
56. Lewis, E.A. & Murphy, K.P. Isothermal titration calorimetry. Methods Mol. Biol. 305, 1-16 (2005).
57. Ladbury, J.E. Calorimetry as a tool for understanding biomolecular interactions and an aid to drug design. Biochem. Soc. Trans. 38, 888-893 (2010).
58. Ladbury, J.E., Klebe, G. & Freire, E. Adding calorimetric data to decision making in lead discovery: A hot tip. Nat. Rev. Drug Discov. 9, 23-27 (2010).
59. Śledź, P. et al. Optimization of the interligand Overhauser effect for fragment linking: Application to inhibitor discovery against Mycobacterium tuberculosis pantothenate synthetase. J. Am. Chem. Soc. 132, 4544-4545 (2012).
60. Good, N.E. et al. Hydrogen ion buffers for biological research. Biochemistry 5, 467-477 (1966).
61. Hwang, T.L. & Shaka, A.J. Water suppression that works. Excitation sculpting using arbitrary wave-forms and pulsed-field gradients. J. Magn. Reson. Ser. A 112, 275-279 (1995).
62. McNicholas, S., Potterton, E., Wilson, K.S. & Noble, M.E.M. Presenting your structures: The CCP4mg molecular-graphics software. Acta. Crystallogr. D Biol. Crystallogr. 67, 386-394 (2011).